Human TWEAK/TNFSF12 DuoSet ELISA, 15 Plate

• Reactivity: Hu
• Applications: ELISA
• Conjugate: Biotin

Human TWEAK/TNFSF12 DuoSet ELISA, 15 Plate Summary

• Source: N/A
• Assay Type: Solid Phase Sandwich ELISA
• Inter-Assay: See PDF Datasheet for details
• Intra-Assay: See PDF Datasheet for details
• Spike Recovery: See PDF Datasheet for details
• Sample Volume: See PDF Datasheet for details
• Gene: TNFSF12

Applications/Dilutions

• Dilutions:
  • ELISA
• Application Notes: No significant interference observed with available related molecules.

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human TWEAK/TNFSF12 DuoSet ELISA, 15 Plate

• APO3 ligand
• APO3LMGC20669
• DR3LGTWEAKAPO3/DR3 ligand
• MGC129581
• TNF-related weak inducer of apoptosis
• TNFSF12
• tumor necrosis factor (ligand) superfamily, member 12
• tumor necrosis factor ligand superfamily member 12
• TWEAK

Background

TWEAK is a type II transmembrane protein belonging to the TNF superfamily. The extracellular domains of human and mouse TWEAK share 89% amino acid sequence identity. A soluble form of TWEAK is generated from the membrane-associated molecule by proteolytic cleavage after Arg 93, suggesting that TWEAK may have long-range effects. TWEAK is expressed widely in many tissues and cells.

Publications for TWEAK/TNFSF12 (DY1090)(15)

Publications using DY1090

• Alehagen, U;Alexander, J;Aaseth, JO;Larsson, A;Svensson, E;Opstad, TB; Effects of an Intervention with Selenium and Coenzyme Q10 on Five Selected Age-Related Biomarkers in Elderly Swedes Low in Selenium: Results That Point to an Anti-Ageing Effect-A Sub-Analysis of a Previous Prospective Double-Blind Placebo-Controlled Randomised Clinical Trial Cells 2023-07-04 [PMID: 37443807] (Human)
• A Altuna-Coy, X Ruiz-Plaza, M Alves-Sant, J Segarra-To, MR Chacón Serum Levels of the Cytokine TWEAK Are Associated with Metabolic Status in Patients with Prostate Cancer and Modulate Cancer Cell Lipid Metabolism In Vitro Cancers, 2021-09-18;13(18):. 2021-09-18 [PMID: 34572917] (Human)
• S Piantoni, F Regola, S Masneri, M Merletti, T Lowin, P Airò, A Tincani, F Franceschi, L Andreoli, G Pongratz Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy Frontiers in Pharmacology, 2021-05-21;12(0):666971. 2021-05-21 [PMID: 34093196] (Human)
• X Ruiz-Plaza, A Altuna-Coy, M Alves-Sant, J Vila-Barja, JF García-Fon, S Martínez-G, J Segarra-To, MR Chacón Liquid Biopsy-Based Exo-oncomiRNAs Can Predict Prostate Cancer Aggressiveness Cancers, 2021-01-11;13(2):. 2021-01-11 [PMID: 33440913] (Human)
• H Wang, S Wang, L Li, X Wang, C Liu, M Lu, Y Xia, Y Liu Involvement of the cytokine TWEAK in the pathogenesis of psoriasis vulgaris, pustular psoriasis, and erythrodermic psoriasis Cytokine, 2020-12-08;138(0):155391. 2020-12-08 [PMID: 33302223] (Human)
• X Ruiz-Plaza, E Rodríguez-, M Alves, A Altuna-Coy, J Lozano-Bar, M Portero-Ot, JF García-Fon, S Martínez-G, J Segarra, MR Chacón Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness J Transl Med, 2019-09-09;17(1):307. 2019-09-09 [PMID: 31500625] (Human)
• J Dereke, J Nilsson, C Nilsson, H Strevens, M Landin-Ols, M Hillman Soluble CD163 and TWEAK in early pregnancy gestational diabetes and later glucose intolerance PLoS ONE, 2019-05-09;14(5):e0216728. 2019-05-09 [PMID: 31071174] (Human)
• M Keshtkar-J, M Ouyang, M Keshtkarja, S Almed, H Li, JD Walston, R Rios, SX Leng Effect of influenza vaccine on tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in older adults Vaccine, 2018-03-13;0(0):. 2018-03-13 [PMID: 29548604] (Human)
• IY Hwang, YS Youm, SD Cho, SW Choi, MH Bae, SJ Park, HW Kim Synovial fluid levels of TWEAK and matrix metalloproteinase 1 in patients with osteoarthritis, and associations with disease severity J Orthop Surg (Hong Kong), 2018-01-01;26(1):2309499018760. 2018-01-01 [PMID: 29486670] (Human)
• Nasar Alwahaibi Evaluation of interleukin-2, interleukin-8, and tumor necrosis factor-like weak inducer of apoptosis in hemodialysis and renal transplant patients and healthy controls Saudi J Kidney Dis Transpl, 2016-11-01;27(6):1123-1128. 2016-11-01 [PMID: 27900956] (Human)
• Sasaki Y, Shimizu Y, Suzuki Y, Horikoshi S, Tomino Y TWEAK/Fn14 system and crescent formation in IgA nephropathy. BMC Nephrol, 2015-03-14;16(0):27. 2015-03-14 [PMID: 25885587] (Human)
• Rojo-Martinez G, Maymo-Masip E, Rodriguez M, Solano E, Goday A, Soriguer F, Valdes S, Chaves F, Delgado E, Colomo N, Hernandez P, Vendrell J, Chacon M Serum sCD163 levels are associated with type 2 diabetes mellitus and are influenced by coffee and wine consumption: results of the Di@bet.es study. PLoS ONE, 2014-06-30;9(6):e101250. 2014-06-30 [PMID: 24978196] (Human)
• Diaz-Lopez A, Bullo M, Chacon M, Estruch R, Vendrell J, Diez-Espino J, Fito M, Corella D, Salas-Salvado J Reduced circulating sTWEAK levels are associated with metabolic syndrome in elderly individuals at high cardiovascular risk. Cardiovasc Diabetol, 2014-02-24;13(0):51. 2014-02-24 [PMID: 24565471] (Human)
• Gaudineau B, Fougere M, Guaddachi F, Lemoine F, de la Grange P, Jauliac S Lipocalin 2, the TNF-like receptor TWEAKR and its ligand TWEAK act downstream of NFAT1 to regulate breast cancer cell invasion. J Cell Sci, 2012-07-05;125(0):4475-86. 2012-07-05 [PMID: 22767506] (Human)
• Chen T, Guo ZP, Li MM, Li JY, Jiao XY, Zhang YH, Liu HJ Tumour necrosis factor-like weak inducer of apoptosis (TWEAK), an important mediator of endothelial inflammation, is associated with the pathogenesis of Henoch-Schonlein purpura. Clin. Exp. Immunol., 2011-07-15;166(1):64-71. 2011-07-15 [PMID: 21762126] (Human)

FAQs for TWEAK/TNFSF12 (DY1090). (Showing 1 - 1 of 1 FAQs).

1. What is the difference between the Quantikine and Duoset ELISA kits?
   • Our Quantikine kits are fully optimized and validated for the sample types listed on the product specific webpage and datasheet, as this can vary between kits. Each kit is supplied ready to use with one pre-coated 96-well plate, a detection antibody directly conjugated to HRP, and all other necessary reagents. These kits are ideal for researchers who want the convenience of a ready to use and optimized ELISA product. Some of these kits are also available prepackaged in larger 6 and 50 plate sizes.Our DuoSet Kits, in contrast, are ELISA development kits containing the capture and detection antibody, the mass-value calibrated standard, and streptavidin-HRP to prepare approximately 5 or 15 plates. Ancillary reagents will need to be used/purchased, and for most kits, we will recommend one of our Ancillary Reagent Kits, which contain the reagents we use ourselves in-house. DuoSet kits are validated only for cell culture supernatant samples and therefore require further development and validation for accurate measurement in more complex samples such as serum and plasma. Our DuoSet Kits offer an economical, flexible alternative for the experienced ELISA user.

Bioinformatics

• Gene Symbol: TNFSF12